CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib‐resistant chronic myeloid leukaemia

Publisher： John Wiley & Sons Inc

E-ISSN： 1555-2039|237|1|14-24

ISSN： 0022-3417

Source： THE JOURNAL OF PATHOLOGY, Vol.237, Iss.1, 2015-09, pp. : 14-24

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 40, Iss. 4, 2015-08 ,pp. : 391-397

John Wiley & Sons Inc

Access to resources Recommend Favorite

Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 5, 2015-06 ,pp. : 683-688

John Wiley & Sons Inc

Access to resources Recommend Favorite

How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 1, 2018-01 ,pp. : 24-32

John Wiley & Sons Inc

Access to resources Recommend Favorite

Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors

By  

INTERNAL MEDICINE JOURNAL, Vol. 48, Iss. S2, 2018-02 ,pp. : 5-13

John Wiley & Sons Inc

Access to resources Recommend Favorite

Nilotinib after imatinib first‐line: a real‐life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 3, 2018-02 ,pp. : 356-364

John Wiley & Sons Inc

Access to resources Recommend Favorite